81584-06-7

Basic information

• Product Name: Xibenolol
• Synonyms: Xibenolol
• CAS NO: 81584-06-7
• Molecular Formula: C15H25NO2
• Molecular Weight: 251.367
• Mol File: 81584-06-7.mol
• Article Data: 6

Chemical Properties

• Melting Point: 57°
• Boiling Point: bp0.7mm 134-136°
• Flash Point: 186.5°C
• Appearance: /
• Density: 0.998g/cm³
• Vapor Pressure: 1.31E-06mmHg at 25°C
• Refractive Index: 1.511
• CAS DataBase Reference: Xibenolol(CAS DataBase Reference)
• NIST Chemistry Reference: Xibenolol(81584-06-7)
• EPA Substance Registry System: Xibenolol(81584-06-7)

Safety Data

• Hazardous Substances Data: 81584-06-7(Hazardous Substances Data)

Usage

Originator

Xibenolol hydrochloride ,Teikoku Hormone

Manufacturing Process

A mixture of (2,3-dimethylphenyl)glycidic ether and t-butylamine in ethanol is heated at reflux for 6 h. The solvent is removed, the residue is washed with water and then extracted with benzene. The dried extract is evaporated to give 1-t-butylamino-1-(2,3-dimethylphenoxy)-2-propanol, melting point 71- 72°C (crystallized from isopropanol).

InChI:InChI=1/C15H25NO2/c1-11-7-6-8-14(12(11)2)18-10-13(17)9-16-15(3,4)5/h6-8,13,16-17H,9-10H2,1-5H3

Upstream product

• 41457-31-2 1,2-epoxy-3-[2,3-dimethylphenoxy]propane 
• 75-64-9 tert-butylamine 
• 256372-73-3 (S)-1-(2',3'-dimethylphenoxy)-2,3-epoxypropane 
• 850427-90-6 (R)-4-(2,3-Dimethyl-phenoxymethyl)-[1,3,2]dioxathiolane 2-oxide 
• 850427-96-2 (R)-4-(2,3-Dimethyl-phenoxymethyl)-[1,3,2]dioxathiolane 2,2-dioxide 
• 526-75-0 2,3-Dimethylphenol 
• 3731-94-0 allyl 2,3-dimethylphenyl ether 
• 850427-86-0 (2S)-1-(2,3-dimethylphenoxy)-2,3-dihydroxypropane 
• 1616790-45-4 (R)-1,2-epoxy-3-(2,3-dimethylphenoxy)propane 

Relevant articles and documents

Synthesis, crystal structure, and absolute configuration of the enantiomers of chiral drug xibenolol hydrochloride

Based on the features of its crystallization, racemic 3-(2,3-dimethylphenoxy)propane-1,2-diol 2, the synthetic precursor of the chiral drug xibenolol 1, was resolved into pure enantiomers by the direct method of entrainment. The enantiomers of diol 2 thro

ANTIHYPERTENSIVE THERAPY

A new use of darusentan is provided in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy with one or more drugs. The composition comprises darusentan in an amount providing a therapeutically effective daily dose; wherein (a) the composition is orally deliverable and/or (b) the daily dose of darusentan is effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures. Further provided is a new use of darusentan in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy, wherein the composition is administered adjunctively with at least one diuretic and at least one antihypertensive drug selected from ACE inhibitors, angiotensin II receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers.

Asymmetric synthesis of aryloxypropanolamines via OsO4-catalyzed asymmetric dihydroxylation

A simple and effective procedure for the enantioselective synthesis of several β-adrenergic blocking agents incorporating the first asymmetric synthesis of celiprolol, is described. The key steps are (i) sharpless asymmetric dihydroxylation of aryl allyl ethers to introduce chirality into the molecules and (ii) conversion of cyclic sulfates into the corresponding epoxides using a three-step procedure.